Ravi Singh

Ravi Singh

Auto-generated profile, based on publicly available information

Ravi Singh

Astbury Centre for Structural and Molecular Biology, University of Leeds

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2021 in ACS Chemical Biology
Verified
Journal Article
Open access
CKCassandra R. Kennedy
Cassandra R. Kennedy
AGAndrea Goya Grocin
Andrea Goya Grocin
TKTristan Kovačič
Tristan Kovačič
RSRavi Singh
Ravi Singh
JWJennifer A. Ward
Jennifer A. Ward
ETEdward W. Tate
Edward W. Tate
Inhibition of inflammasome and pyroptotic pathways are promising strategies for clinical treatment of autoimmune and inflammatory disorders. MCC950, a potent inhibitor of the NLR-family inflammasome pyrin domain-containing 3 (NLRP3) protein, has shown encouraging results in animal models for a range of conditions; however, until now, no off-targets have been identified. Herein, we report the design, synthesis, and application of a novel photoaffinity alkyne-tagged probe for MCC950 (IMP2070) which shows direct engagement with NLRP3 and inhibition of inflammasome activation in macrophages. Affinity-based chemical proteomics in live macrophages identified several potential off-targets, including carbonic anhydrase 2 (CA2) as a specific target of IMP2070, and independent cellular thermal proteomic profiling revealed stabilization of CA2 by MCC950. MCC950 displayed noncompetitive inhibition of CA2 activity, confirming carbonic anhydrase as an off-target class for this compound. These data highlight potential biological mechanisms through which MCC950 and derivatives may exhibit off-target effects in preclinical or clinical studies.

25 February 2020 in Journal of Chemical Education
Verified
Journal Article
Closed access
NMNimesh Mistry
Nimesh Mistry
RSRavi Singh
Ravi Singh
JRJamie Ridley
Jamie Ridley

23 August 2024 in eLife
Verified
Journal Article
Open access
EBEmma Brown
Emma Brown
GSGemma Swinscoe
Gemma Swinscoe
DLDaniella Andrea Lefteri
Daniella Andrea Lefteri
RSRavi Singh
Ravi Singh
AMAmy Moran
Amy Moran
SGStephen Griffin
Stephen Griffin
Flaviviruses , including Zika virus (ZIKV), are a significant global health concern, yet no licensed antivirals exist to treat disease. The small membrane (M) protein plays well-defined roles during viral egress and remains within virion membranes following release and maturation. However, it is unclear whether M plays a functional role in this setting. Here, we show that M forms oligomeric membrane-permeabilising channels in vitro, with increased activity at acidic pH and sensitivity to the prototypic channel-blocker, rimantadine. Accordingly, rimantadine blocked an early stage of ZIKV cell culture infection. Structure-based channel models, comprising hexameric arrangements of two trans -membrane domain protomers were shown to comprise more stable assemblages than other oligomers using molecular dynamics simulations. Models contained a predicted lumenal rimantadine-binding site, as well as a second druggable target region on the membrane-exposed periphery. In silico screening enriched for repurposed drugs/compounds predicted to bind to either one site or the other. Hits displayed superior potency in vitro and in cell culture compared with rimantadine, with efficacy demonstrably linked to virion-resident channels. Finally, rimantadine effectively blocked ZIKV viraemia in preclinical models, supporting that M constitutes a physiologically relevant target. This could be explored by repurposing rimantadine, or development of new M-targeted therapies.

17 December 2020 in Journal of Chemical Education
Verified
Journal Article
Closed access
RSRavi Singh
Ravi Singh
ZLZhonghan Li
Zhonghan Li
RFRichard Foster
Richard Foster
NMNimesh Mistry
Nimesh Mistry

21 October 2026 in eLife
Verified
Journal Article
Open access
EBEmma Brown
Emma Brown
GSGemma Swinscoe
Gemma Swinscoe
DLDaniella Andrea Lefteri
Daniella Andrea Lefteri
RSRavi Singh
Ravi Singh
AMAmy Moran
Amy Moran
SGStephen Griffin
Stephen Griffin

20 June 2025 in ACS Chemical Biology
Verified
Journal Article
Open access
LSLior Soday
Lior Soday
CSChotima Seripracharat
Chotima Seripracharat
JGJanine L. Gray
Janine L. Gray
ALAndré F. S. Luz
André F. S. Luz
RHRyan T. Howard
Ryan T. Howard
ETEdward W. Tate
Edward W. Tate
Necroptosis is a form of programmed cell death that, when dysregulated, is associated with cancer and inflammatory and neurodegenerative diseases. Here, starting from hits identified from a phenotypic high-throughput screen for inhibitors of necroptosis, we synthesized a library of compounds containing a 7-phenylquinoline motif and validated their anti-necroptotic activity in a novel live-cell assay. Based on these data, we designed an optimized photoaffinity probe for target engagement studies and through biochemical and cell-based assays established receptor-interacting kinase 1 (RIPK1) as the cellular target, with inhibition of necroptosis arising from the prevention of RIPK1 autophosphorylation and activation. X-ray crystallography and mass spectrometry revealed that these compounds bind at the hinge region of the active conformation of RIPK1, establishing them as type I kinase inhibitors. In addition, we demonstrated in vitro synergy with type III kinase inhibitors, such as necrostatin-1 and found that lead compounds protected mice against acute inflammation in necroptosis models in vivo. Overall, we present a novel pharmacophore for inhibition of human RIPK1, a key protein involved in necroptosis, and provide a photoaffinity probe to explore RIPK1 target engagement in cells.